Development of an HPLC method for monitoring of Photofrin II therapy
To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer. After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography...
Gespeichert in:
| Veröffentlicht in: | Clinical biochemistry 2005, Vol.38 (1), p.73-78 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 78 |
|---|---|
| container_issue | 1 |
| container_start_page | 73 |
| container_title | Clinical biochemistry |
| container_volume | 38 |
| creator | Vogeser, Michael Schaffer, Moshe Egeler, Emil Spöhrer, Ute |
| description | To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer.
After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography with fluorescence detection was performed. Plasma porphyrin concentrations were monitored in five patients that were treated with Photofrin II.
The method proved linear over a wide concentration range, precise, and applicable in a routine clinical laboratory setting.
The method described here will enable large-scale clinical pharmacokinetic studies on Photofrin II; investigations can now address possible correlations between individual concentrations of drug-derived plasma porphyrins and systemic photosensitivity—representing the main side effect of Photofrin II—with the perspective of individualized light protection regimens after Photofrin II administration. |
| doi_str_mv | 10.1016/j.clinbiochem.2004.09.014 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67328978</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0009912004002528</els_id><sourcerecordid>67328978</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-bdba1af47a3202123d975aa2c9c2c94d5e42f4d80e03c53572aafd88c6ba19033</originalsourceid><addsrcrecordid>eNqNkE1LAzEQhoMoWj_-gqwXb7tOkv3KUVq1hYIe9ByyyaxN2d3UZCv035vSgh49hGHgefMyDyF3FDIKtHxYZ7qzQ2OdXmGfMYA8A5EBzU_IhNYVT5ng_JRMAECkgjK4IJchrOPK8ro8Jxe0KKHiDCZkNsNv7Nymx2FMXJuoIZm_LadJj-PKmaR1PundYEfn7fC5B95WbnRt3JLFIhlX6NVmd03OWtUFvDnOK_Lx_PQ-nafL15fF9HGZal4VY9qYRlHV5pWK1YwybkRVKMW00PHlpsCctbmpAYHrghcVU6o1da3LmBPA-RW5P_y78e5ri2GUvQ0au04N6LZBlvGmWlR1BMUB1N6F4LGVG2975XeSgtwrlGv5R6HcK5QgZFQYs7fHkm3To_lNHp1FYHoAMJ76bdHLoC0OGo31qEdpnP1HzQ8m8YfD</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67328978</pqid></control><display><type>article</type><title>Development of an HPLC method for monitoring of Photofrin II therapy</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Vogeser, Michael ; Schaffer, Moshe ; Egeler, Emil ; Spöhrer, Ute</creator><creatorcontrib>Vogeser, Michael ; Schaffer, Moshe ; Egeler, Emil ; Spöhrer, Ute</creatorcontrib><description>To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer.
After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography with fluorescence detection was performed. Plasma porphyrin concentrations were monitored in five patients that were treated with Photofrin II.
The method proved linear over a wide concentration range, precise, and applicable in a routine clinical laboratory setting.
The method described here will enable large-scale clinical pharmacokinetic studies on Photofrin II; investigations can now address possible correlations between individual concentrations of drug-derived plasma porphyrins and systemic photosensitivity—representing the main side effect of Photofrin II—with the perspective of individualized light protection regimens after Photofrin II administration.</description><identifier>ISSN: 0009-9120</identifier><identifier>EISSN: 1873-2933</identifier><identifier>DOI: 10.1016/j.clinbiochem.2004.09.014</identifier><identifier>PMID: 15607320</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antineoplastic Agents - pharmacology ; Chemistry Techniques, Analytical - methods ; Chromatography, High Pressure Liquid - methods ; Dihematoporphyrin Ether - pharmacology ; HPLC ; Humans ; Photochemotherapy ; Photodynamic therapy ; Photofrin II ; Phototoxicity ; Plasma - drug effects ; Plasma - metabolism ; Porphyrins ; Porphyrins - chemistry ; Porphyrins - metabolism ; Radiodynamic therapy ; Time Factors</subject><ispartof>Clinical biochemistry, 2005, Vol.38 (1), p.73-78</ispartof><rights>2004 The Canadian Society of Clinical Chemists</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-bdba1af47a3202123d975aa2c9c2c94d5e42f4d80e03c53572aafd88c6ba19033</citedby><cites>FETCH-LOGICAL-c375t-bdba1af47a3202123d975aa2c9c2c94d5e42f4d80e03c53572aafd88c6ba19033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.clinbiochem.2004.09.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,4024,27923,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15607320$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vogeser, Michael</creatorcontrib><creatorcontrib>Schaffer, Moshe</creatorcontrib><creatorcontrib>Egeler, Emil</creatorcontrib><creatorcontrib>Spöhrer, Ute</creatorcontrib><title>Development of an HPLC method for monitoring of Photofrin II therapy</title><title>Clinical biochemistry</title><addtitle>Clin Biochem</addtitle><description>To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer.
After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography with fluorescence detection was performed. Plasma porphyrin concentrations were monitored in five patients that were treated with Photofrin II.
The method proved linear over a wide concentration range, precise, and applicable in a routine clinical laboratory setting.
The method described here will enable large-scale clinical pharmacokinetic studies on Photofrin II; investigations can now address possible correlations between individual concentrations of drug-derived plasma porphyrins and systemic photosensitivity—representing the main side effect of Photofrin II—with the perspective of individualized light protection regimens after Photofrin II administration.</description><subject>Antineoplastic Agents - pharmacology</subject><subject>Chemistry Techniques, Analytical - methods</subject><subject>Chromatography, High Pressure Liquid - methods</subject><subject>Dihematoporphyrin Ether - pharmacology</subject><subject>HPLC</subject><subject>Humans</subject><subject>Photochemotherapy</subject><subject>Photodynamic therapy</subject><subject>Photofrin II</subject><subject>Phototoxicity</subject><subject>Plasma - drug effects</subject><subject>Plasma - metabolism</subject><subject>Porphyrins</subject><subject>Porphyrins - chemistry</subject><subject>Porphyrins - metabolism</subject><subject>Radiodynamic therapy</subject><subject>Time Factors</subject><issn>0009-9120</issn><issn>1873-2933</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1LAzEQhoMoWj_-gqwXb7tOkv3KUVq1hYIe9ByyyaxN2d3UZCv035vSgh49hGHgefMyDyF3FDIKtHxYZ7qzQ2OdXmGfMYA8A5EBzU_IhNYVT5ng_JRMAECkgjK4IJchrOPK8ro8Jxe0KKHiDCZkNsNv7Nymx2FMXJuoIZm_LadJj-PKmaR1PundYEfn7fC5B95WbnRt3JLFIhlX6NVmd03OWtUFvDnOK_Lx_PQ-nafL15fF9HGZal4VY9qYRlHV5pWK1YwybkRVKMW00PHlpsCctbmpAYHrghcVU6o1da3LmBPA-RW5P_y78e5ri2GUvQ0au04N6LZBlvGmWlR1BMUB1N6F4LGVG2975XeSgtwrlGv5R6HcK5QgZFQYs7fHkm3To_lNHp1FYHoAMJ76bdHLoC0OGo31qEdpnP1HzQ8m8YfD</recordid><startdate>2005</startdate><enddate>2005</enddate><creator>Vogeser, Michael</creator><creator>Schaffer, Moshe</creator><creator>Egeler, Emil</creator><creator>Spöhrer, Ute</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2005</creationdate><title>Development of an HPLC method for monitoring of Photofrin II therapy</title><author>Vogeser, Michael ; Schaffer, Moshe ; Egeler, Emil ; Spöhrer, Ute</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-bdba1af47a3202123d975aa2c9c2c94d5e42f4d80e03c53572aafd88c6ba19033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Antineoplastic Agents - pharmacology</topic><topic>Chemistry Techniques, Analytical - methods</topic><topic>Chromatography, High Pressure Liquid - methods</topic><topic>Dihematoporphyrin Ether - pharmacology</topic><topic>HPLC</topic><topic>Humans</topic><topic>Photochemotherapy</topic><topic>Photodynamic therapy</topic><topic>Photofrin II</topic><topic>Phototoxicity</topic><topic>Plasma - drug effects</topic><topic>Plasma - metabolism</topic><topic>Porphyrins</topic><topic>Porphyrins - chemistry</topic><topic>Porphyrins - metabolism</topic><topic>Radiodynamic therapy</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vogeser, Michael</creatorcontrib><creatorcontrib>Schaffer, Moshe</creatorcontrib><creatorcontrib>Egeler, Emil</creatorcontrib><creatorcontrib>Spöhrer, Ute</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical biochemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vogeser, Michael</au><au>Schaffer, Moshe</au><au>Egeler, Emil</au><au>Spöhrer, Ute</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of an HPLC method for monitoring of Photofrin II therapy</atitle><jtitle>Clinical biochemistry</jtitle><addtitle>Clin Biochem</addtitle><date>2005</date><risdate>2005</risdate><volume>38</volume><issue>1</issue><spage>73</spage><epage>78</epage><pages>73-78</pages><issn>0009-9120</issn><eissn>1873-2933</eissn><abstract>To develop and to validate a method to quantify plasma porphyrins after application of Photofrin II, a drug preparation that is used for photodynamic therapy (PDT) and as a radiosensitizer.
After solid phase extraction of postdose plasma samples, reversed phase high performance-liquid chromatography with fluorescence detection was performed. Plasma porphyrin concentrations were monitored in five patients that were treated with Photofrin II.
The method proved linear over a wide concentration range, precise, and applicable in a routine clinical laboratory setting.
The method described here will enable large-scale clinical pharmacokinetic studies on Photofrin II; investigations can now address possible correlations between individual concentrations of drug-derived plasma porphyrins and systemic photosensitivity—representing the main side effect of Photofrin II—with the perspective of individualized light protection regimens after Photofrin II administration.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15607320</pmid><doi>10.1016/j.clinbiochem.2004.09.014</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0009-9120 |
| ispartof | Clinical biochemistry, 2005, Vol.38 (1), p.73-78 |
| issn | 0009-9120 1873-2933 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67328978 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Antineoplastic Agents - pharmacology Chemistry Techniques, Analytical - methods Chromatography, High Pressure Liquid - methods Dihematoporphyrin Ether - pharmacology HPLC Humans Photochemotherapy Photodynamic therapy Photofrin II Phototoxicity Plasma - drug effects Plasma - metabolism Porphyrins Porphyrins - chemistry Porphyrins - metabolism Radiodynamic therapy Time Factors |
| title | Development of an HPLC method for monitoring of Photofrin II therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A32%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20an%20HPLC%20method%20for%20monitoring%20of%20Photofrin%20II%20therapy&rft.jtitle=Clinical%20biochemistry&rft.au=Vogeser,%20Michael&rft.date=2005&rft.volume=38&rft.issue=1&rft.spage=73&rft.epage=78&rft.pages=73-78&rft.issn=0009-9120&rft.eissn=1873-2933&rft_id=info:doi/10.1016/j.clinbiochem.2004.09.014&rft_dat=%3Cproquest_cross%3E67328978%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67328978&rft_id=info:pmid/15607320&rft_els_id=S0009912004002528&rfr_iscdi=true |